摘要
目的探讨尤瑞克林联合奥扎格雷钠治疗急性脑梗死的效果和安全性。方法选取2015年1月～2016年10月在我院住院的100例急性脑梗死患者作为研究对象,按患者就诊的先后顺序将其随机分为治疗组和对照组,每组各50例。两组患者均给予内科常规治疗,治疗组患者给予尤瑞克林联合奥扎格雷钠治疗,对照组患者给予丹参治疗。比较两组患者治疗前后的神经功能缺损(NIHSS)评分、格拉斯哥昏迷量表(GCS)评分及治疗效果、不良反应情况。结果两组患者治疗前的NIHSS评分及GCS评分比较,差异无统计学意义(P>0.05);两组患者治疗后的NIHSS评分均明显低于治疗前,GCS评分均明显高于治疗前,差异有统计学意义(P<0.05);治疗组患者治疗后的NIHSS评分为(9.87±5.19)分,明显低于对照组的(14.36±7.28)分,GCS评分为(13.90±1.10)分,明显高于对照组的(10.50±1.70)分,差异有统计学意义(P<0.05)。治疗组患者的治疗总有效率(94%)明显高于对照组(72%),差异有统计学意义(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论尤瑞克林联合奥扎格雷钠治疗急性脑梗死安全有效。
Objetive To explore the clinical effect and safety of Urinary Kallidinogenase combined with Ozagrelin in the treatment of acute cerebral infarction.Methods A total of 100 patients with acute cerebral infarction hospitalized in our hospital from January 2015 to October 2016 were selected as objects and they were randomly divided into the treatment group and the control group according to the admission order of patients,with 50 cases in each group.Both groups of patients were given routine medical treatment.Patients in the treatment group were treated with Urinary Kallidinogenase combined with Ozagrelin,while the control group was treated with Radix Salvia Miltiorrhiza.The neurological deficit(NIHSS)scores and the Glasgow coma scale(GCS)scores before and after treatment,the treatment effect,and the adverse reactions were compared between the two groups.Results There were no significant differences in NIHSS scores and GCS scores between the two groups before treatment(P>0.05).The NIHSS scores of the two groups after treatment were significantly lower than those before treatment,and the GCS scores were significantly higher than those before treatment,and the differences were statistically significant.The score of NIHSS after treatment in the treatment group was(9.87±5.19)points,which was significantly lower than that in the control group accounting for(14.36±7.28)points,and the score of GCS was(13.90±1.10)points,which was significantly higher than that in the control group accounting for(10.50±1.70)points,with statistically significant differences(P<0.05).The total effective rate of treatment in the treatment group(94%)was significantly higher than that in the control group(72%),and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Urinary Kallidinogenase combined with Ozagrelin in the treatment of acute cerebral infarction is safe and effective.
作者
利伟江
罗玉媚
李光宁
LI Wei-jiang;LUO Yu-mei;LI Guang-ning(Department of Neurology,People′s Hospital of Huadu District in Guangzhou City,Guangdong Province,Guangzhou510800,China)
出处
《中国当代医药》
2018年第34期91-94,共4页
China Modern Medicine
关键词
尤瑞克林
奥扎格雷钠
急性脑梗死
Urinary Kallidinogenase
Ozagrelin
Acute cerebral infarction
